Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets Indicate Bullish Outlook for Axsome Therapeutics

Elaine Mendonca by Elaine Mendonca
January 16, 2024
in Breaking News
0
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

As of January 16, 2024, the outlook for Axsome Therapeutics (NASDAQ:AXSM) appears to be largely positive based on recent analyst ratings and price targets. Over the past three months, the average price target for AXSM has been $119.29, with a high estimate of $180.00 and a low estimate of $108.00. This average target of $135.67 represents a substantial increase of 50.74% from the previous average price target of $90.00.

In the current month, AXSM has received 25 Buy Ratings, 1 Hold Rating, and 0 Sell Ratings from analysts. Notably, key analysts have taken actions such as raising price targets and maintaining buy ratings, which reflects their confidence in the company’s performance.

Here is a summary of the recent analyst ratings and price targets:

– David Amsellem from Piper Sandler has raised the rating to Overweight with a current price target of $113.00, up from the prior target of $90.00.
– Raghuram Selvaraju from HC Wainwright & Co. has maintained a Buy rating with a price target of $180.00.
– Charles Duncan from Cantor Fitzgerald has maintained an Overweight rating with a price target of $108.00.
– David Hoang from Citigroup has announced a Buy rating with a price target of $125.00.

The majority of analysts have given buy or overweight ratings, and their price targets are significantly higher than the current price. This indicates a positive sentiment towards the future performance of Axsome Therapeutics.

In conclusion, the analyst landscape for Axsome Therapeutics suggests a bullish outlook. The majority of analysts maintain buy ratings and have significantly increased their price targets, demonstrating confidence in the company’s future prospects.

AXSM Stock: Strong Performance and Positive Momentum in After-Hours Trading – January 16, 2024

On January 16, 2024, AXSM stock displayed a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. The price of AXSM shares experienced a slight decrease of $0.26 since the market closed, representing a drop of 0.31%. However, in after-hours trading, AXSM stock showed a positive momentum by rising $0.28. Investors may find AXSM stock appealing due to its strong performance relative to its 52-week range and the fact that it is trading above its 200-day simple moving average. It is important to note that stock prices can be influenced by various factors, including market conditions, company news, and economic trends. Therefore, it is crucial for investors to conduct thorough research and analysis before making any investment decisions.

AXSM Stock Performance: Mixed Results on January 16, 2024 – Importance of Monitoring Financial Reports and Market Factors

On January 16, 2024, AXSM stock experienced a mixed performance, with some positive and negative indicators. The net income for the company was reported to be -$187.13 million in the previous year, representing a 43.5% decrease compared to the previous year. However, there has been a slight improvement in the net income since the last quarter, with a reported figure of -$62.20 million, indicating a 7.4% increase. Similarly, the EPS for the previous year stood at -$4.60, showing a decrease of 32.79% compared to the previous year. However, there has been a positive change in EPS since the last quarter, with a reported figure of -$1.32, indicating a 14.17% increase. While the decrease in net income and EPS over the past year may raise concerns for investors, the recent improvements in these figures since the last quarter could be seen as a positive sign. However, it is important to note that without the total revenue data, it is challenging to gauge the overall financial performance of AXSM accurately. Investors and analysts should closely monitor AXSM’s financial reports, including the total revenue figures, to gain a more accurate understanding of the company’s financial health. It is also advisable to consider other factors such as market trends, industry performance, and any significant developments or announcements from AXSM that may impact its stock performance. In conclusion, AXSM’s stock performance on January 16, 2024, showcased a mixed bag of results. Investors should exercise caution and closely monitor AXSM’s financial reports and other market factors to make informed investment decisions.

Tags: AXSM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
SO stock news

Goldman Sachs CEO Optimistic for Positive Shift in Credit Card Partnerships

Technology Robotics Markets and money

Analyst Shows Confidence in Adtran with Buy Rating and Solid Price Target

Telecommunications Industry stock Trading

EchoStar Receives Coverage Initiation Following Successful Merger A Dominant Global Connectivity Leader Emerges

Recommended

Peloton Stock

Peloton’s Pivotal Moment: All Eyes on Quarterly Results

3 days ago
Technology Data analytics Stock Bull Market

Palantir Technologies Inc Sees Stock Rise with University Partnership and Surge in Demand

2 years ago
Finance_Capitalization

Analyst Reiterates Outperform Rating and Increases Price Target for Pennant Gr

2 years ago
Finance_Business (2)

ECB Launches Investigation into Grifols SAs Financial Manipulation Allegations

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Spectrum Brands Faces Critical Test as Major Investor Exits

Veritone Faces Critical Earnings Test Amid Surging Analyst Optimism

Olo’s Moment of Truth: Q3 Earnings to Test Record Rally

Daikin Stock Faces Critical Test with Quarterly Results

ProSiebenSat.1 Shares Face Mounting Challenges as Outlook Dims

Zion Oil Shares Face Critical Test with Quarterly Report Looming

Trending

Oil-Dri of America Stock
Analysis

Market Enigma: Oil-Dri of America Posts Record Results as Shares Lag

by Robert Sasse
November 5, 2025
0

A curious divergence is unfolding for Oil-Dri of America. The company is celebrating its most successful fiscal...

Performance Food Stock

Performance Food Shares Tumble as Profit Plunge Overshadows Record Revenue

November 5, 2025
Ingles Markets Stock

Ingles Markets Shares Surge on Strong Institutional Backing

November 5, 2025
Spectrum Brands Stock

Spectrum Brands Faces Critical Test as Major Investor Exits

November 5, 2025
Veritone Stock

Veritone Faces Critical Earnings Test Amid Surging Analyst Optimism

November 5, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Market Enigma: Oil-Dri of America Posts Record Results as Shares Lag
  • Performance Food Shares Tumble as Profit Plunge Overshadows Record Revenue
  • Ingles Markets Shares Surge on Strong Institutional Backing

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com